Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) will report its fourth quarter and full year 2020 financial results on February 4, 2021, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. ET on the same day. Participants can access the call by dialing 888-455-0391 within the U.S. or 773-756-0467 internationally. The earnings release and live webcast will be available on Quest's investor website.
Hackensack Meridian Health and Quest Diagnostics announced a partnership to enhance diagnostic services across New Jersey. Under a long-term agreement, Quest will manage lab operations for 11 Hackensack hospitals. The financial details remain undisclosed. Quest aims to improve patient outcomes by utilizing its extensive New Jersey testing infrastructure, including a new flagship lab in Clifton slated for 2021. This collaboration marks Quest's largest laboratory services agreement to date, promising better access and quality of care.
Summary not available.
Quest Diagnostics (NYSE: DGX) and The Commons Project announced a collaboration to enhance control over health data access, allowing individuals to view lab results and vaccination records through the CommonHealth app. The initiative aims to facilitate safer international travel and economic recovery by providing digital access to COVID-19 test results. With approximately 55% of U.S. residents using Android, this partnership positions Quest to leverage a significant user base for improving health decision-making.
Quest Diagnostics (DGX) has raised its financial outlook for full year 2020, anticipating net revenues of at least $9.35 billion, up from a previous estimate of $8.8 billion. The company expects a 21.0% revenue increase and reported diluted EPS of at least $9.98. Despite a decline in organic testing volumes in December, COVID-19 molecular testing volumes have exceeded prior expectations. The revised outlook includes cash from operations of at least $1.95 billion and capital expenditures around $420 million.
Summary not available.
Summary not available.
Quest Diagnostics (NYSE: DGX) announced collaborations with Montefiore Nyack Hospital and Goshen Hospital to enhance diagnostic services. The relationships will include management of hospital laboratories, supply chain management, and esoteric reference testing. Steve Rusckowski, CEO, highlighted the increasing demand from health systems for Quest's laboratory strategy support. As Quest serves a significant portion of the U.S. population, these partnerships aim to improve healthcare management and patient outcomes while addressing the challenges faced by hospitals.
Quest Diagnostics (DGX) declared a quarterly cash dividend of $0.56 per share, payable on February 3, 2021. Shareholders must be on record by January 20, 2021 to receive the dividend. The company aims to empower health improvements, servicing a significant portion of adult Americans and healthcare providers in the United States. Quest Diagnostics continues to utilize its diagnostic insights for better health outcomes.
Quest Diagnostics (NYSE: DGX) announced its participation in the Credit Suisse 29th Annual Virtual Healthcare Conference. CEO Steve Rusckowski will present on the company's vision, growth strategy, and operational excellence, focusing on the COVID-19 pandemic's impact. The event will take place on November 10, 2020, at 11:45 a.m. ET. The presentation will be webcast live and available afterward on the company's investor relations page until December 10, 2020. Quest Diagnostics continues to lead in COVID-19 testing and diagnostics, providing essential healthcare services.